Agree that was my take. The HIV LATCH study is int
Post# of 151591
“The Company will be prioritizing oncology in 2025, as we believe this indication holds the potential for the highest value return to the Company in the form of a significant partnership and/or drug approval“
This was the most interesting statement, considering that we are going to be doing a combination with Pfizer‘s drug?

